Clinical Trial Update: Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial of vortioxetine monotherapy for major depressive disorder in patients with type 2 diabetes was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Type 2 Diabetes Mellitus

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Todd Doyle | Conditions: Type2 Diabetes, Major Depressive Disorder | Phase 4 | Status: WITHDRAWN